u/amira_dumitru

Read the published reimbursement criteria where I live rather than asking. Took twenty minutes and answered everything.

What pack size is that price for?

Agreed on the plan-year point. Criteria that applied last year may simply not apply now.

the formulary is published, read it before you appeal

Disagreeing with this line: the deadline runs from the letter date and treating it otherwise is expensive.

a peer-to-peer call is often faster than a written appeal

the second-level appeal is where things actually turn

deadlines run from the letter date, not from when you opened it

Adding the underused one — external review. Independent, binding where it applies, and hardly anybody gets that far.

post the whole document, not the headline number

Ask what the stability statement was written against — temperature, light, and whether it was the lyophilised powder or the reconstituted solution. Those are three different claims.

pack sizes differ, so per-month comparisons need care

the second-level appeal is where things actually turn

Apotheke pricing and pharmacy pricing elsewhere are different systems

Correction: that is net peptide content, not purity. Different number, different meaning, and the document says so if you read the row label.

Right, and keeping every date and reference number turns a frustrating process into an auditable one.

LC-MS gives you identity; UV purity gives you a relative quantity. A document with the first and not the second, or the reverse, is answering half the question.

cross-border prescription rules exist and they are narrower than people think

Why step therapy denials feel unfair and are nonetheless beatable.

Disagreeing with this line: the deadline runs from the letter date and treating it otherwise is expensive.

Appeal deadlines run from the date on the determination letter.

Disagreeing with this line: the deadline runs from the letter date and treating it otherwise is expensive.

Cross-border prescription recognition exists under EU rules but is conditional and narrower than commonly assumed, with requirements about the prescription’s form and content.

UV at 214nm sees the peptide bond and picks up almost everything; at 280nm you are looking at aromatics only. Which wavelength the number came from is part of the number.

Are you comparing the same presentation, or different pack sizes?

Agreed — the itemised related substances table is the difference between a document and a receipt.

Step therapy requires documented trial of preferred alternatives. It is not an argument to be won on merits; it is a record to be produced, and the record is what the appeal must contain.

prior authorisation criteria change every plan year

Marketing authorisation is granted centrally for these products; reimbursement, pricing and prescribing criteria are national competences. Those are decided by different bodies with different processes.

Yes — and the reason to ask for the whole page is that the interesting parts are the ones people crop out to fit a screenshot.

Correction: that is net peptide content, not purity. Different number, different meaning, and the document says so if you read the row label.

the counterion is part of the mass you paid for

Yes — quoting their own policy bulletin back at them is far more effective than arguing in general terms.

Push back: your plan is an employer plan, which changes both the appeal path and who the regulator is.

Disagreeing with this line: the deadline runs from the letter date and treating it otherwise is expensive.

Employer-sponsored plans may be regulated differently from individually purchased ones, which changes both the appeal route and which regulator hears a complaint.

That is not what the method line says. It names the technique; it does not certify the operator.

The PDF creation date being later than the analysis date is usually a re-issue or a re-export. It is worth one question and it is not evidence of anything on its own.

Correcting myself upthread: the criterion I quoted was updated for this year.

Published reimbursement criteria exist in most member states and are usually available in the national language. They are the authoritative answer to eligibility questions that this board can only guess at.

Small fix — those two prices are for different pack sizes, which accounts for most of the gap.

Not convinced — cross-border prescription recognition is narrower than you are describing and the exceptions matter.

Adding the practical step — read your own country’s published criteria. They exist and they are definitive.

Agreed on asking for the storage condition. It is one line and it changes how you read the entire stability claim.